Asia
The research showed that 61% of patients with PV experienced a complete hematological response after 7.5 years of treatment with BESREMi. Here’s more about it.
The investigational drug directs a patient’s own IL-2 toward immune activation while simultaneously preventing IL-2’s immune suppression activities.
It was another busy week for clinical trial news. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Sungho Han, Ph.D., founder and CEO of Genuv Inc. in Seoul, South Korea, has built her career and her company by thinking outside the box.
Biopharma and life sciences organizations from across the globe provide updates on their pipelines and businesses.
Monday was a big day for LianBio, as the Shanghai-based company launched on the Nasdaq with an impressive $325 million initial public offering (IPO).
This novel diagnostic technology uses augmented reality and a smartphone or tablet to administer cognitive and functional tests.
One year after snagging $310 million in a financing round, LianBio raised $325M in its initial public offering. Its stock begins selling today on Nasdaq under the ticker symbol “LIAN.”
As the world marks a grim milestone of 5 million COVID-19 deaths, public health officials are keeping a close watch on a substrain of the Delta variant.
PRESS RELEASES